Cargando…
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799711/ https://www.ncbi.nlm.nih.gov/pubmed/35091541 http://dx.doi.org/10.1038/s41408-022-00621-9 |
| _version_ | 1784642120164835328 |
|---|---|
| author | Wang, Huafeng Yang, Chang Shi, Ting Zhang, Yi Qian, Jiejing Wang, Yungui Hu, Yongxian Mao, Liping Ye, Xiujin Liu, Fang Xi, Zhenfang Shou, Lihong Fu, Caiyun Naranmandura, Hua Jin, Jie Zhu, Hong-Hu |
| author_facet | Wang, Huafeng Yang, Chang Shi, Ting Zhang, Yi Qian, Jiejing Wang, Yungui Hu, Yongxian Mao, Liping Ye, Xiujin Liu, Fang Xi, Zhenfang Shou, Lihong Fu, Caiyun Naranmandura, Hua Jin, Jie Zhu, Hong-Hu |
| author_sort | Wang, Huafeng |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8799711 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87997112022-02-07 Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia Wang, Huafeng Yang, Chang Shi, Ting Zhang, Yi Qian, Jiejing Wang, Yungui Hu, Yongxian Mao, Liping Ye, Xiujin Liu, Fang Xi, Zhenfang Shou, Lihong Fu, Caiyun Naranmandura, Hua Jin, Jie Zhu, Hong-Hu Blood Cancer J Correspondence Nature Publishing Group UK 2022-01-28 /pmc/articles/PMC8799711/ /pubmed/35091541 http://dx.doi.org/10.1038/s41408-022-00621-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Wang, Huafeng Yang, Chang Shi, Ting Zhang, Yi Qian, Jiejing Wang, Yungui Hu, Yongxian Mao, Liping Ye, Xiujin Liu, Fang Xi, Zhenfang Shou, Lihong Fu, Caiyun Naranmandura, Hua Jin, Jie Zhu, Hong-Hu Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia |
| title | Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia |
| title_full | Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia |
| title_fullStr | Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia |
| title_full_unstemmed | Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia |
| title_short | Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia |
| title_sort | venetoclax-ponatinib for t315i/compound-mutated ph+ acute lymphoblastic leukemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799711/ https://www.ncbi.nlm.nih.gov/pubmed/35091541 http://dx.doi.org/10.1038/s41408-022-00621-9 |
| work_keys_str_mv | AT wanghuafeng venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT yangchang venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT shiting venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT zhangyi venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT qianjiejing venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT wangyungui venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT huyongxian venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT maoliping venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT yexiujin venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT liufang venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT xizhenfang venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT shoulihong venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT fucaiyun venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT naranmandurahua venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT jinjie venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia AT zhuhonghu venetoclaxponatinibfort315icompoundmutatedphacutelymphoblasticleukemia |